A RAD51 assay feasible in routine tumor samples calls PARP inhibitor response beyond BRCA mutation

EMBO Molecular Medicine

  ^{1    2    3    4    5    6    7    8    8    8    9    1,10    1,11    1,12    1,12    1,12    1,12    1,12    1,12    1,12    1,13    1,14    1,15    1,16    1,17    1,18    1,19    2,20    2,20    2,20    2,21    2,22    2,22    2,22    2,23    2,24    2,25    2,25    2,25} 

[1] AstraZeneca, Waltham, MA, USA;CHU de Quebec ‐ Université Laval Research Center, Genomics Center, CHUL, Québec City, QC, Canada;CIBERONC, Instituto de Salud Carlos III, Madrid, Spain;Breast Surgical Unit, Breast Cancer Center, Hospital Vall d'Hebron, Universitat Autònoma de Barcelona, Barcelona, Spain;CIBERONC, Instituto de Salud Carlos III, Madrid, Spain;Department of Oncology, Ramón y Cajal University Hospital, Madrid, Spain;Vall d'Hebron Institute of Oncology, Barcelona, Spain;CIBERONC, Instituto de Salud Carlos III, Madrid, Spain;Molecular Oncology Group, Vall d'Hebron Institute of Oncology, Barcelona, Spain;Cancer Research UK Cambridge Institute and Department of Oncology, Li Ka Shing Centre, University of Cambridge, Cambridge, UK;Cancer Research UK Cambridge Institute and Department of Oncology, Li Ka Shing Centre, University of Cambridge, Cambridge, UK;Breast Cancer Programme, Cancer Research UK (CRUK) Cambridge Cancer Centre, Cambridge, UK;Department of Medical Oncology, Hospital Vall d'Hebron, Universitat Autònoma de Barcelona, Barcelona, Spain;Breast Cancer and Melanoma Group, Vall d'Hebron Institute of Oncology, Barcelona, Spain;Department of Pathology, Dalhousie University, Halifax, NS, Canada;Department of Radiology, Hospital Vall d'Hebron, Universitat Autònoma de Barcelona, Barcelona, Spain;Division of Molecular Pathology and Cancer Genomics, The Netherlands Cancer Institute, Amsterdam, The Netherlands;Experimental Therapeutics Group, Vall d'Hebron Institute of Oncology, Barcelona, Spain;Experimental Therapeutics Group, Vall d'Hebron Institute of Oncology, Barcelona, Spain;CIBERONC, Instituto de Salud Carlos III, Madrid, Spain;Experimental Therapeutics Group, Vall d'Hebron Institute of Oncology, Barcelona, Spain;Department of Medical Oncology, University Hospital of Parma, Parma, Italy;Experimental Therapeutics Group, Vall d'Hebron Institute of Oncology, Barcelona, Spain;High Risk and Familial Cancer Group, Vall d'Hebron Institute of Oncology, Barcelona, Spain;Department of Medical Oncology, Hospital Vall d'Hebron, Universitat Autònoma de Barcelona, Barcelona, Spain;Genome Stability Laboratory, CHU de Québec Research Center, Québec City, QC, Canada;Department of Molecular Biology, Medical Biochemistry and Pathology, Laval University Cancer Research Center, Québec City, QC, Canada;Genome Stability Laboratory, CHU de Québec Research Center, Québec City, QC, Canada;Department of Molecular Biology, Medical Biochemistry and Pathology, Laval University Cancer Research Center, Québec City, QC, Canada;CHU de Quebec ‐ Université Laval Research Center, Genomics Center, CHUL, Québec City, QC, Canada;High Risk and Familial Cancer Group, Vall d'Hebron Institute of Oncology, Barcelona, Spain;Department of Medical Oncology, Hospital Vall d'Hebron, Universitat Autònoma de Barcelona, Barcelona, Spain;Human Oncology and Pathogenesis Program (HOPP), Memorial Sloan Kettering Cancer Center, New York, NY, USA;Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY, USA;Oncogenetics Group, Vall d'Hebron Institute of Oncology, Barcelona, Spain;Oncogenetics Group, Vall d'Hebron Institute of Oncology, Barcelona, Spain;Clinical and Molecular Genetics Area, Hospital Vall d'Hebron, Universitat Autònoma de Barcelona, Barcelona, Spain;Oncology Data Science (OdysSey Group), Vall d'Hebron Institute of Oncology, Barcelona, Spain;Oncology Innovative Medicines and Early Clinical Development Biotech Unit, AstraZeneca, Cambridge, UK;Pathology Department, Vall d'Hebron University Hospital, Barcelona, Spain;CIBERONC, Instituto de Salud Carlos III, Madrid, Spain;XenTech, Evry, France;

关键词: BRCA;    homologous recombination;    PALB;    PARP;    RAD;   

DOI  :  10.15252/emmm.201809172

来源: publisher

【 授权许可】

Unknown